Chimeric TherapeuticsCHMMF -96.67%13 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 707 Biotechnology companies, Chimeric Therapeutics ranks better than 90.66% on this metric.
The historical rank and industry rank for Chimeric Therapeutics's Days Payable or its related term are showing as below:
CHMMF'
s Days Payable Range Over the Past 10 Years
Min: 2104.46 Med: 2104.46 Max: 2104.46
Current: 2104.46
During the past 5 years, Chimeric Therapeutics's highest Days Payable was 2104.46. The lowest was 2104.46. And the median was 2104.46.
CHMMF's Days Payable is ranked better than 90.66% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs CHMMF: 2104.46
Chimeric Therapeutics's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Chimeric Therapeutics Days Payable Related Terms
Chimeric Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHMMF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Chimeric Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics (CHMMF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chimeric Therapeutics and its competitors. Over the past decade, Chimeric Therapeutics' Days Payable has ranged from 2,104.46 to 2,104.46. According to the industry distribution chart, Chimeric Therapeutics ranks #66 out of 707 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Chimeric Therapeutics' Days Payable too high?
Chimeric Therapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 2,104.46 to a high of 2,104.46. Based on the distribution chart, Chimeric Therapeutics ranks #66 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #66 out of 707 companies for Days Payable. This places Chimeric Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Historically, Chimeric Therapeutics' own Days Payable has ranged from 2,104.46 to 2,104.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Days Payable of 0.00. The current Days Payable is 0.00. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
